Skip to main content

Table 1 Select ongoing and pending clinical trials that allow prior treatment with a PD-1 or PD-L1 inhibitor

From: Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

Clinicaltrials.gov identifier Experimental agents Regimen targets Phase Tumor type
NCT02899078 Nivolumab + Ibrutinib PD-1 + BTK 1b/2 RCC
NCT02923531 Nivolumab + X4P-001 PD-1 + CXCR4 1b/2a RCC
NCT02963610* Pembrolizumab + Lenalidomide PD-1 + immunomodulatory 1/2 NSCLC
NCT03083808 Pembrolizumab + Docetaxel/Pemetrexed/Gemcitabine PD-1 + Chemotherapy 2 NSCLC
NCT03041181 Nivolumab + Docetaxel PD-1 + Chemotherapy 2 NSCLC
NCT02437136 Pembrolizumab + Entinostat PD-1 + HDAC 1b/2 NSCLC and melanoma
NCT02959437 Pembrolizumab + Azacitidine + Epacadostat PD-1 + Chemotherapy + IDO-1 1/2 NSCLC**
NCT03084640 Pembrolizumab + CMP-001 PD-1 + TLR9 1b/2 melanoma
NCT03014648 Atezolizumab PD-L1 2 NSCLC
  1. PD-1 programmed cell death protein 1, BTK: Bruton’s tyrosine kinase, RCC: renal cell carcinoma, CXCR4: C-X-C chemokine receptor type 4, NSCLC: non-small cell lung cancer, HDAC: histone deacetylases, IDO-1: Indoleamine 2,3-Dioxygenase 1, TLR9: Toll-like receptor 9, PD-L1 programmed death-ligand 1
  2. *Prior treatment with anti-PD-1/PD-L1 is only allowed for the Phase 2 portion of this trial (which is only for NSCLC patients)
  3. **Only the NSCLC cohort allows prior treatment with PD-1/PD-L1
  4. Please note that this table was constructed using the following search terms on clinicaltrials.gov on 5/12/2017: “Nivolumab AND previously treated”, “Pembrolizumab AND previously treated”, and “Atezolizumab AND previously treated”. After generating a list of trials, the eligibility criteria for each trial was manually screened for inclusion in this table